Thalidomide moves back into the public eye

ROCKVILLE, Md. - FDA approval of thalidomide and its subsequent widespread use could result in some cases of birth defects, but this possibility should not deter FDA from approving it as a treatment for erythema nodosum leprosum (ENL), a painful condition associated with Hanson's disease (leprosy), the chairman of an FDA advisory panel said on Friday.

At the end of two days of public deliberations about potential safety issues associated with the use of thalidomide for ENL, Dermatologic and Ophthalmic Drugs Advisory Committee chairman Joseph McGuire Jr. said widespread use could lead to some

Read the full 938 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE